Objective
In the developed countries, prostate cancer is the second leading cause of cancer-associated death in men, with a predicted rate of 10.9/100.000 men in Europe in 2016. Mortality results when prostate cancer has spread to other organs (metastasis, particularly to the bone). Prostate cancer prognosis and follow-up is mainly performed with routine blood test (prostate specific antigen levels). However, the low/high risk of metastasis for individual patients cannot always be accurately assessed due to tumor heterogeneity and differential rate of tumor progression. Thus, a more thorough understanding of the metastatic processes is needed.
Complex molecular interactions and cellular processes between the cancer (stem) cells and the surrounding tissue microenvironment (supportive stroma) are required for tumor growth and metastasis. Cancer cells hijack the normal microenvironment to orchestrate metastatic events and acquisition of resistance to drug treatments. To increase our understanding of the metastatic mechanisms we sought to identify and modulate the molecular properties of aggressive tumor cells and the reciprocal supportive stroma in unique xenograft models and eventually assess the prognostic value of the identified parameters.
We propose to investigate the following objectives:
1) identify the molecular signature of tumor and supportive stroma in metastatic patient-derived xenografts
2) elucidate the molecular mechanisms of the tumor- supportive stroma
3) determine their prognostic value in clinical blood samples as predictors of disease progression and metastasis risk.
Understanding the mechanisms of prostate cancer (re)initiation will provide the foundation for proper prognostic tool development for the identification of high risk patient groups.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine oncology prostate cancer
- social sciences sociology demography mortality
- medical and health sciences medical biotechnology tissue engineering
- natural sciences mathematics pure mathematics mathematical analysis functional analysis
- engineering and technology medical engineering medical laboratory technology laboratory samples analysis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3012 Bern
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.